These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 37341001)

  • 1. Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies.
    Kim KH; Lee HW; Ha HK; Seo HK
    Investig Clin Urol; 2023 May; 64(3):202-218. PubMed ID: 37341001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives.
    Kim IH; Lee HJ
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
    Szabados B; Kockx M; Assaf ZJ; van Dam PJ; Rodriguez-Vida A; Duran I; Crabb SJ; Van Der Heijden MS; Pous AF; Gravis G; Herranz UA; Protheroe A; Ravaud A; Maillet D; Mendez MJ; Suarez C; Linch M; Prendergast A; Tyson C; Stanoeva D; Daelemans S; Rombouts M; Mariathasan S; Tea JS; Mousa K; Sharma S; Aleshin A; Banchereau R; Castellano D; Powles T
    Eur Urol; 2022 Aug; 82(2):212-222. PubMed ID: 35577646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscle invasive bladder cancer: where is the field headed?
    Ghatalia P; Kaur J; Sonpavde G
    Expert Opin Biol Ther; 2023; 23(9):913-927. PubMed ID: 37477127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.
    Meeks JJ; Bellmunt J; Bochner BH; Clarke NW; Daneshmand S; Galsky MD; Hahn NM; Lerner SP; Mason M; Powles T; Sternberg CN; Sonpavde G
    Eur Urol; 2012 Sep; 62(3):523-33. PubMed ID: 22677572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant therapy for muscle-invasive bladder cancer.
    Jain RK; Sonpavde G
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):603-614. PubMed ID: 32546025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
    Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
    J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer.
    Macleod LC; Yabes JG; Yu M; Fam MM; Hale NE; Turner RM; Lopa SH; Gingrich JR; Borza T; Skolarus TA; Davies BJ; Jacobs BL
    Urol Oncol; 2019 Jul; 37(7):462-469. PubMed ID: 31053530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer.
    Nadal R; Apolo AB; Girardi DM; Hahn NM; Bellmunt J
    Urol Oncol; 2023 Jan; 41(1):27-34. PubMed ID: 34756410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
    BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative chemotherapy for muscle invasive bladder cancer.
    Rudzinski JK; Basappa NS; North S
    Curr Opin Support Palliat Care; 2015 Sep; 9(3):249-54. PubMed ID: 26125306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.
    Funt SA; Rosenberg JE
    Nat Rev Clin Oncol; 2017 Apr; 14(4):221-234. PubMed ID: 27874062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an
    Satkunasivam R; Lim K; Teh BS; Guzman J; Zhang J; Farach A; Chen SH; Wallis CJ; Efstathiou E; Esnaola NF; Sonpavde GP
    Future Oncol; 2022 Aug; 18(25):2771-2781. PubMed ID: 35703113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Perioperative Therapy for Muscle Invasive Bladder Cancer.
    Ma J; Black PC
    Hematol Oncol Clin North Am; 2021 Jun; 35(3):495-511. PubMed ID: 33958147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Therapy for Cisplatin Ineligible Muscle Invasive Bladder Cancer Patients: A Review of Available Evidence.
    Narain TA; Tosh JM; Gautam G; Talwar HS; Panwar VK; Mittal A; Mandal AK
    Urology; 2021 Aug; 154():8-15. PubMed ID: 33775784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant versus Adjuvant Chemotherapy in Patients with Resectable Muscle-Invasive Bladder Cancer.
    Sawasdee A; Tanthanuch M; Bejrananda T
    Asian Pac J Cancer Prev; 2022 Nov; 23(11):3641-3647. PubMed ID: 36444575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience.
    Abdelrahman I; Aboulkassem H; Elazab A; Abdallah AY; Ismail Y; Taher M
    J Egypt Natl Canc Inst; 2023 May; 35(1):13. PubMed ID: 37145329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.
    Milowsky MI; Rumble RB; Booth CM; Gilligan T; Eapen LJ; Hauke RJ; Boumansour P; Lee CT
    J Clin Oncol; 2016 Jun; 34(16):1945-52. PubMed ID: 27001593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.